Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Recruiting
N/A
Interventional Study
Breast Cancer, Metastatic
Breast Cancer Invasive
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 93 (estimated)
- Sponsor
- ScreenCell · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
INCLUSION CRITERIA
For all participants :
* Female with age greater than or equal to 18 years
For participants with metastatic breast cancer:
\- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line…
Contacts